That’s a great way to frame it — persistence as proof of correct upstream assembly. Once LN priming is understood as an actively governed layer (more on that in a few hours) rather than a passive bottleneck, it forces a rethink not just of why checkpoints fail, but when they make sense.
There’s a tumor context where that mismatch between upstream assembly and downstream amplification becomes impossible to ignore (more on that later this week, I had to scratch an itch that had been bugging me yesterday which culminated in an article that will be out tomorrow).
MDNA-11 is positioned to be a primary enabling therapy in modern immuno-oncology!!!!
That’s a great way to frame it — persistence as proof of correct upstream assembly. Once LN priming is understood as an actively governed layer (more on that in a few hours) rather than a passive bottleneck, it forces a rethink not just of why checkpoints fail, but when they make sense.
There’s a tumor context where that mismatch between upstream assembly and downstream amplification becomes impossible to ignore (more on that later this week, I had to scratch an itch that had been bugging me yesterday which culminated in an article that will be out tomorrow).